Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits.
The purpose of this study was to compare the topical anti-inflammatory effects of the nonselective cyclooxygenase (COX) inhibitor, ketorolac, with the selective COX-2 inhibitor, nimesulide, in an animal model of dry eye in albino rabbits. All animals were examined by the Schirmer test, tear break-up time (TBUT) and fluorescein corneal staining test. Dry eye model showed significant reduction in tear volume, TBUT, corneal staining and histopathological signs of dryness and inflammation. On treating dry eye model with nimesulide 0.1% eye drops and ketorolac 0.5% eye drops, there were improvements in Schirmer test values, TBUT and fluorescein corneal staining and histopathologically reduced inflammatory reaction, with signs of healing and regeneration. Both nimesulide and ketorolac ameliorate atropine sulphate induced dry eye in albino rabbits. The use of selective COX-2 inhibitor, nimesulide, is preferred to avoid local and systemic side effects which may occur with the use of the nonselective COX inhibitor, ketorolac.
El-Shazly
Amany Hassan Mohamed
AH
Ocular Pharmacology Department, Research Institute of Ophthalmology, Giza, Egypt. Amany.namaky@yahoo.com
El-Gohary
Amal Ahmad
AA
El-Shazly
Laila Hassan Mohamed
LH
El-Hossary
Ghada Ghanem
GG
D000287:Administration, Topical; D000818:Animals; D001285:Atropine; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D015352:Dry Eye Syndromes / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D005123:Eye / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D020910:Ketorolac / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009883:Ophthalmic Solutions; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011817:Rabbits; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D013666:Tears / Q000378:metabolism; D013997:Time Factors
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D001285:Atropine; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C012655:nimesulide; D020910:Ketorolac